New York-based clinical trial intelligence company Lokavant recently announced the expansion of its global customer base and additions to its leadership team.
According to a press release published by PR Newswire, Lokavant has agreed to a multi-year enterprise partnership with the CMIC Group, a Japanese contract research organization.
The partnership is expected to help Lokavant expand its presence in the Asia-Pacific region, as well as place its platform at the center of CMIC's technology and innovation strategy, the company said in the release.
"Like most drug development companies in our region, our data were previously siloed across different teams, source systems, and studies,” Yoshihito Kondo, executive vice president of clinical operations at CMIC, said in the release. "These insights have already helped drive a step-change in performance across our enterprise, and enable better time, cost, and quality outcomes for sponsors here in APAC.”
Kondo expressed excitement about the partnership.
“We are excited to expand our strategic partnership and to make Lokavant our clinical trial intelligence solution across all future trials,” Kondo said in the release. “As the APAC market continues to grow, this partnership will help solidify CMIC's leadership position, driving better, data-driven clinical operations to the region and delivering critical therapies to patients in need.”
Lokavant has also formed a partnership with Perficient, a global digital consultancy.
“Through this partnership, Lokavant and Perficient will address pervasive clinical data challenges with integrated technology products and services, unifying trial data to power sophisticated analytics,” the release stated. “Thanks to Lokavant's ability to connect to any clinical and operational data source, the platform will integrate seamlessly into Perficient's existing deployments and accelerate impact on new implementations.”